RxDoctor Payments Data

Edward Schellinck, MD

General Practice · Turlock, CANPI 1487614137

Payments from drug & device makers

$1,173in general payments, 2019–2025

Across 37 payments — averaging $31.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$187
  • Lilly USA, LLC$179
  • AbbVie$162
  • AstraZeneca$153
  • GSK$125
  • Nestle Healthcare Nutrition Inc.$104
  • plus $264 from 9 others

What the payments were for

  • Food & beverage$1,173100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,173 in reported general payments places this provider in the 80th percentile of 12,963 general practice providers in California.

See all general practice providers in California

Medicare billing

Part B allowed, 2024
$46,149
Medicare patients
108
Services billed
405

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide126$140,724
JardianceEmpagliflozin94$115,952
EliquisApixaban62$73,583
FarxigaDapagliflozin Propanediol50$66,125
RybelsusSemaglutide29$57,467
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$46,012
XareltoRivaroxaban25$32,822
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog46$30,031
Bydureon BciseExenatide Microspheres12$26,358
JanuviaSitagliptin Phosphate18$24,985
LinzessLinaclotide23$16,214
MounjaroTirzepatide15$14,462
Tresiba Flextouch U-200Insulin Degludec12$11,697
Rosuvastatin Calcium485$11,386
Tresiba Flextouch U-100Insulin Degludec13$11,033

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$187$198,191155 claims
PfizerEliquis$53$73,58362 claims
AstraZenecaFarxiga$153$66,12550 claims
GSKTrelegy Ellipta$125$46,01260 claims
AbbVieLinzess$162$16,21423 claims
Lilly USA, LLCMounjaro$179$14,46215 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$66$4,02215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 12,963 general practice providers in California.

Other general practice in Turlock

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →